Detailed Stock Analysis: Dr. Reddy's Laboratories Limited

Overview:

Dr. Reddy's Laboratories Limited is an integrated pharmaceutical company operating globally. It has segments for Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The company offers a wide range of pharmaceutical products for various therapeutic categories and has a significant presence in the healthcare sector.

Key Financial Statistics:

• Current Price: INR 6534.15
• Market Cap: INR 1.09 trillion
• Dividend Yield: 0.61%
• 52-Week High: INR 6575.00
• 52-Week Low: INR 5076.25

Company Officers:

The company is led by a team of experienced officers including the Chairman, CEO, CFO, and other key members who bring diverse expertise to the organization.

Key Ratios and Margins:

• Profit Margin: 19.95%
• Return on Assets: 11.51%
• Debt to Equity: 7.14
• Operating Margin: 18.31%
• Gross Margins: 58.61%

Analyst Recommendations:

• Number of Analyst Opinions: 34
• Target Mean Price: INR 6153.74
• Recommendation: Hold

Conclusion:

Dr. Reddy's Laboratories Limited presents a strong financial standing with a robust presence in the pharmaceutical industry. With a focus on innovation and a diverse product portfolio, the company is well-positioned for future growth.